IP Library Granted Patent US 8,329,860
Granted Patent B2
US 8,329,860 · App. 12/443,011 · Granted Dec 11, 2012

Chromatography ligand comprising domain C from

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,329,860
App. No.
12/443,011
Granted
Dec 11, 2012
Kind
B2
Abstract

The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

Claims (14)

1. A chromatography ligand, which ligand comprises one or more Domain C units from Staphylococcus protein A (SpA), wherein the Domain C sequence is the amino acid sequence as defined by SEQ ID NO 2, further wherein after 5 hours incubation in 0.5 M NaOH the ligand retains at least 95% of its binding capacity compared to the untreated ligand.

2. The ligand of claim 1 , which is capable of binding to the Fab part of an antibody.

3. The ligand of claim 1 , which further comprises a terminal coupling group.

4. The ligand of claim 3 , wherein the terminal group comprises arginine or cysteine.

5. The ligand of claim 3 , wherein the terminal coupling group comprises at least one of nitrogen or sulphur atom(s).

6. A multimeric chromatography ligand, which contains at least two Domain C units, as defined in claim 1 .

7. The ligand of claim 6 , which in addition to said at least two Domain C units, also comprises one or more other protein-based units.

8. The ligand of claim 6 , which comprises 2-8 Domain C units, optionally coupled via linker segments.

9. A chromatography matrix comprised of ligands as defined in claim 1 coupled to at least one insoluble carrier.

10. A Fab fragment-binding chromatography matrix comprising the ligand of claim 1 coupled to at least one insoluble carrier.

11. The matrix of claim 10 , wherein the carrier is comprised of substantially spherical particles.

12. The matrix of claim 9 , wherein the carrier is porous.

13. A method of preparing a chromatography matrix, which method comprises providing ligands as defined in claim 1 ; and coupling said ligands to at least one porous carrier.

14. The method of claim 13 , wherein the coupling is carried out via a nitrogen or sulphur atom of the ligand.

Assignments (3)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 038811/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2009
From: HALL, MARTIN; LARSSON, STURE; MURANYI, ANDREAS; RODRIGO, GUSTAV; ZOU, JINYU; ABERG, PER-MIKAEL
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 022454/0786 →